CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
作者信息
Naik Jyoti, Themeli Maria, de Jong-Korlaar Regina, Ruiter Ruud W J, Poddighe Pino J, Yuan Huipin, de Bruijn Joost D, Ossenkoppele Gert J, Zweegman Sonja, Smit Linda, Mutis Tuna, Martens Anton C M, van de Donk Niels W C J, Groen Richard W J
机构信息
Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, the Netherlands.
Department of Clinical Genetics, Amsterdam UMC, VU University Medical Center, Amsterdam, the Netherlands.
出版信息
Haematologica. 2019 Mar;104(3):e100-e103. doi: 10.3324/haematol.2018.192757. Epub 2018 Sep 6.
Abstract
摘要
相似文献
1
CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Haematologica. 2019 Mar;104(3):e100-e103. doi: 10.3324/haematol.2018.192757. Epub 2018 Sep 6.
2
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.
Blood. 2018 Mar 1;131(9):995-999. doi: 10.1182/blood-2017-07-794214. Epub 2018 Jan 5.
3
Frequent, high density expression of surface CD38 as a potential therapeutic target in adult T-lineage acute lymphoblastic leukemia.
Haematologica. 2024 Feb 1;109(2):661-665. doi: 10.3324/haematol.2023.283814.
4
Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia.
Blood Adv. 2024 Aug 13;8(15):3875-3879. doi: 10.1182/bloodadvances.2024013212.
5
The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells.
Curr Cancer Drug Targets. 2012 Jan;12(1):51-63. doi: 10.2174/156800912798888992.
6
Myeloid/NK cell acute leukemia with unique blast morphology: de novo or secondary leukemia?
Int J Hematol. 2013 Oct;98(4):509-11. doi: 10.1007/s12185-013-1441-6. Epub 2013 Sep 18.
7
[Acute lymphoblastic leukemia with T + PH1 monocytosis: a case report].
Ann Biol Clin (Paris). 2011 Jul-Aug;69(4):473-5. doi: 10.1684/abc.2011.0595.
8
Drugging DNA repair to target T-ALL cells.
Leuk Lymphoma. 2018 Jul;59(7):1746-1749. doi: 10.1080/10428194.2017.1397662. Epub 2017 Nov 8.
9
[Successful treatment with clarithromycin for Mixed phenotype acute leukemia, T/myeloid, NOS].
Rinsho Ketsueki. 2010 Apr;51(4):297-9.
10
Retinoic acid induction of CD38 antigen expression on normal and leukemic human myeloid cells: relationship with cell differentiation.
Leuk Lymphoma. 2003 Apr;44(4):691-8. doi: 10.1080/1042819031000060564.
引用本文的文献
1
CAR-T cell therapy for cancer: current challenges and future directions.
Signal Transduct Target Ther. 2025 Jul 4;10(1):210. doi: 10.1038/s41392-025-02269-w.
2
Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions.
Int J Mol Sci. 2025 May 10;26(10):4571. doi: 10.3390/ijms26104571.
3
Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemia.
Nat Commun. 2025 Apr 23;16(1):3804. doi: 10.1038/s41467-025-59040-6.
4
Engineering innate immune cells for cancer immunotherapy.
Nat Biotechnol. 2025 Apr;43(4):516-533. doi: 10.1038/s41587-025-02629-5. Epub 2025 Apr 14.
5
Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies.
Discov Oncol. 2025 Jan 26;16(1):89. doi: 10.1007/s12672-025-01797-9.
6
Membrane Antigen Targeting in Acute Myeloid Leukemia Using Antibodies or CAR-T Cells.
Cancers (Basel). 2024 Oct 28;16(21):3627. doi: 10.3390/cancers16213627.
7
Remodeling of the bone marrow microenvironment during acute myeloid leukemia progression.
Ann Transl Med. 2024 Aug 1;12(4):63. doi: 10.21037/atm-23-1824. Epub 2024 Jan 15.
8
Recent advances in CAR-T therapy for the treatment of acute myeloid leukemia.
Ther Adv Hematol. 2024 Jul 23;15:20406207241263489. doi: 10.1177/20406207241263489. eCollection 2024.
9
The clinical efficacy of a daratumumab-based regimen in relapsed/refractory acute leukemia: a single-center experience.
Ann Hematol. 2024 Oct;103(10):4057-4063. doi: 10.1007/s00277-024-05892-9. Epub 2024 Jul 24.
10
CAR-T Cells in Acute Myeloid Leukemia: Where Do We Stand?
Biomedicines. 2024 May 28;12(6):1194. doi: 10.3390/biomedicines12061194.
本文引用的文献
1
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.
Blood. 2018 Mar 1;131(9):995-999. doi: 10.1182/blood-2017-07-794214. Epub 2018 Jan 5.
2
CD38 antibodies in multiple myeloma: back to the future.
Blood. 2018 Jan 4;131(1):13-29. doi: 10.1182/blood-2017-06-740944. Epub 2017 Nov 8.
3
Immunotherapy in adult acute leukemia.
Leuk Res. 2017 Sep;60:63-73. doi: 10.1016/j.leukres.2017.06.011. Epub 2017 Jun 29.
4
Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation.
Exp Hematol. 2017 Aug;52:12-23. doi: 10.1016/j.exphem.2017.04.007. Epub 2017 Apr 27.
5
Management of adults with T-cell lymphoblastic leukemia.
Blood. 2017 Mar 2;129(9):1134-1142. doi: 10.1182/blood-2016-07-692608. Epub 2017 Jan 23.
6
All-trans retinoic acid enhances cytotoxic effect of T cells with an anti-CD38 chimeric antigen receptor in acute myeloid leukemia.
Clin Transl Immunology. 2016 Dec 9;5(12):e116. doi: 10.1038/cti.2016.73. eCollection 2016 Dec.
7
Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches.
Blood. 2016 Dec 22;128(25):2949-2959. doi: 10.1182/blood-2016-05-719021. Epub 2016 Oct 12.
8
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
Blood. 2016 Jul 21;128(3):384-94. doi: 10.1182/blood-2015-12-687749. Epub 2016 May 24.
9
All-trans retinoic acid and interferon-α increase CD38 expression on adult T-cell leukemia cells and sensitize them to T cells bearing anti-CD38 chimeric antigen receptors.
Blood Cancer J. 2016 May 13;6(5):e421. doi: 10.1038/bcj.2016.30.
10
Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid.
Blood. 2016 Jan 28;127(4):458-63. doi: 10.1182/blood-2015-07-653840. Epub 2015 Nov 18.
Zotero 插件